788 million adults were estimated to have chronic kidney disease in 2023, up from 378 million in 1990, making it the ninth leading cause of death globally. Access to kidney replacement therapy varies by a factor of 200 between high-income regions and low-income countries.
Transplant immunosuppressants, oncology orals and nephrology binders sit inside one range of 135, with 32 injectable presentations.
Range depth
Tacrolimus from 0.25mg.
Hormone-receptor and antiandrogen lines.
Phosphate binder and calcimimetic lines.
7 tamsulosin and dutasteride presentations.
We establish what is already registered in your market, who supplies it today, and where demand is going unmet.
We set your current range against the portfolio and separate genuine gaps from lines you already stock.
You get the molecules in filing order, which of them need a dossier built for your authority, and which fall outside the range.
We compile the dossier in CTD format for your authority and supply the COPP and plant-level WHO-GMP and PIC/S certificates behind it.
We analyse your market and set your existing range against the portfolio, then return the molecules worth filing in priority order with the documentation route for each.